JP2013514761A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013514761A5 JP2013514761A5 JP2012543268A JP2012543268A JP2013514761A5 JP 2013514761 A5 JP2013514761 A5 JP 2013514761A5 JP 2012543268 A JP2012543268 A JP 2012543268A JP 2012543268 A JP2012543268 A JP 2012543268A JP 2013514761 A5 JP2013514761 A5 JP 2013514761A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- stranded nucleic
- double
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims description 76
- 125000003729 nucleotide group Chemical group 0.000 claims description 76
- 108020004707 nucleic acids Proteins 0.000 claims description 65
- 102000039446 nucleic acids Human genes 0.000 claims description 65
- 150000007523 nucleic acids Chemical class 0.000 claims description 62
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 50
- 230000000692 anti-sense effect Effects 0.000 claims description 35
- 108091081021 Sense strand Proteins 0.000 claims description 29
- 239000002336 ribonucleotide Substances 0.000 claims description 27
- 108091028664 Ribonucleotide Proteins 0.000 claims description 26
- 235000000346 sugar Nutrition 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 15
- 238000012986 modification Methods 0.000 claims description 14
- 230000004048 modification Effects 0.000 claims description 14
- 206010016654 Fibrosis Diseases 0.000 claims description 13
- 230000004761 fibrosis Effects 0.000 claims description 11
- 208000035657 Abasia Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- -1 β-D-erythrofuranosyl Chemical group 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 230000014509 gene expression Effects 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 108020004635 Complementary DNA Proteins 0.000 claims description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 2
- 238000010804 cDNA synthesis Methods 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 5
- KKZFLSZAWCYPOC-VPENINKCSA-N Deoxyribose 5-phosphate Chemical group O[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KKZFLSZAWCYPOC-VPENINKCSA-N 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 206010072877 Intestinal fibrosis Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 206010028537 myelofibrosis Diseases 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- 210000001260 vocal cord Anatomy 0.000 claims 2
- FGODUFHTWYYOOB-UHFFFAOYSA-N 1,3-diaminopropan-2-yl dihydrogen phosphate Chemical compound NCC(CN)OP(O)(O)=O FGODUFHTWYYOOB-UHFFFAOYSA-N 0.000 claims 1
- MPCAJMNYNOGXPB-UHFFFAOYSA-N 1,5-anhydrohexitol Chemical class OCC1OCC(O)C(O)C1O MPCAJMNYNOGXPB-UHFFFAOYSA-N 0.000 claims 1
- NXEGRTVWWNBQLW-UHFFFAOYSA-N 12-aminododecyl dihydrogen phosphate Chemical compound NCCCCCCCCCCCCOP(O)(O)=O NXEGRTVWWNBQLW-UHFFFAOYSA-N 0.000 claims 1
- KUQZVISZELWDNZ-UHFFFAOYSA-N 3-aminopropyl dihydrogen phosphate Chemical compound NCCCOP(O)(O)=O KUQZVISZELWDNZ-UHFFFAOYSA-N 0.000 claims 1
- HYCSHFLKPSMPGO-UHFFFAOYSA-N 3-hydroxypropyl dihydrogen phosphate Chemical compound OCCCOP(O)(O)=O HYCSHFLKPSMPGO-UHFFFAOYSA-N 0.000 claims 1
- XYVLZAYJHCECPN-UHFFFAOYSA-N 6-aminohexyl phosphate Chemical compound NCCCCCCOP(O)(O)=O XYVLZAYJHCECPN-UHFFFAOYSA-N 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010031023 Oral submucosal fibrosis Diseases 0.000 claims 1
- 206010034665 Peritoneal fibrosis Diseases 0.000 claims 1
- 208000031472 Retinal fibrosis Diseases 0.000 claims 1
- 125000002015 acyclic group Chemical group 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000001273 butane Substances 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 231100000012 chronic liver injury Toxicity 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000005207 oral submucous fibrosis Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000004303 peritoneum Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 239000005451 thionucleotide Substances 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 9
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 7
- 239000005547 deoxyribonucleotide Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 244000089409 Erythrina poeppigiana Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical class OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical class F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 210000001726 chromosome structure Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28514909P | 2009-12-09 | 2009-12-09 | |
| US61/285,149 | 2009-12-09 | ||
| US30741210P | 2010-02-23 | 2010-02-23 | |
| US61/307,412 | 2010-02-23 | ||
| US37207210P | 2010-08-09 | 2010-08-09 | |
| US61/372,072 | 2010-08-09 | ||
| PCT/US2010/059578 WO2011072082A2 (en) | 2009-12-09 | 2010-12-08 | Modulation of hsp47 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015006421A Division JP5972408B2 (ja) | 2009-12-09 | 2015-01-16 | Ｈｓｐ４７発現の調節 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013514761A JP2013514761A (ja) | 2013-05-02 |
| JP2013514761A5 true JP2013514761A5 (enExample) | 2014-07-17 |
| JP5685267B2 JP5685267B2 (ja) | 2015-03-18 |
Family
ID=44146170
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012543268A Active JP5685267B2 (ja) | 2009-12-09 | 2010-12-08 | Ｈｓｐ４７発現の調節 |
| JP2015006421A Active JP5972408B2 (ja) | 2009-12-09 | 2015-01-16 | Ｈｓｐ４７発現の調節 |
| JP2016020615A Active JP6197057B2 (ja) | 2009-12-09 | 2016-02-05 | Ｈｓｐ４７発現の調節 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015006421A Active JP5972408B2 (ja) | 2009-12-09 | 2015-01-16 | Ｈｓｐ４７発現の調節 |
| JP2016020615A Active JP6197057B2 (ja) | 2009-12-09 | 2016-02-05 | Ｈｓｐ４７発現の調節 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8710209B2 (enExample) |
| EP (3) | EP3434773A3 (enExample) |
| JP (3) | JP5685267B2 (enExample) |
| KR (3) | KR101692063B1 (enExample) |
| CN (3) | CN106701758B (enExample) |
| AU (1) | AU2010328104B2 (enExample) |
| CA (1) | CA2781896C (enExample) |
| DK (1) | DK2509991T3 (enExample) |
| ES (1) | ES2562499T3 (enExample) |
| IL (2) | IL219804A (enExample) |
| PL (1) | PL2509991T3 (enExample) |
| PT (1) | PT2509991E (enExample) |
| TW (3) | TWI543763B (enExample) |
| WO (1) | WO2011072082A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009221164A (ja) | 2008-03-17 | 2009-10-01 | Nitto Denko Corp | 肺線維症処置剤 |
| US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
| AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
| RU2711531C2 (ru) * | 2010-06-17 | 2020-01-17 | Нитто Денко Корпорейшн | Средство для лечения фиброза почек |
| JP5950428B2 (ja) | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
| CN103370416A (zh) | 2010-12-02 | 2013-10-23 | 第一三共株式会社 | 修饰的单链多核苷酸 |
| TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
| US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
| CN103998454A (zh) * | 2011-08-03 | 2014-08-20 | 夸克制药公司 | 用于治疗听力障碍和平衡障碍的双链寡核苷酸化合物 |
| KR20250133484A (ko) * | 2011-11-18 | 2025-09-05 | 알닐람 파마슈티칼스 인코포레이티드 | 변형된 ＲＮＡｉ 제제 |
| US20140323550A1 (en) * | 2011-11-18 | 2014-10-30 | Nitto Denko Corporation | Intestinal fibrosis treatment agent |
| CA2895077A1 (en) * | 2011-12-12 | 2013-06-20 | Beverly Packard | In vivo delivery of oligonucleotides |
| RU2014125496A (ru) | 2012-01-12 | 2016-02-27 | Кварк Фармасьютикалс, Инк. | Комбинированная терапия для лечения нарушений слуха и равновесия |
| US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
| JP6340162B2 (ja) | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
| JP7011389B2 (ja) * | 2013-06-12 | 2022-01-26 | オンコイミューニン，インコーポレイティド | オリゴヌクレオチドの全身性イン－ビボ送達 |
| WO2015051366A2 (en) * | 2013-10-04 | 2015-04-09 | Novartis Ag | Novel formats for organic compounds for use in rna interference |
| CN105683163B (zh) * | 2013-10-04 | 2018-11-09 | 诺华股份有限公司 | RNA干扰中使用的RNAi剂的3’端帽 |
| US9976142B2 (en) | 2014-04-02 | 2018-05-22 | Nitto Denko Corporation | Targeting molecule and a use thereof |
| JP6480467B2 (ja) | 2014-04-07 | 2019-03-13 | 日東電工株式会社 | 疎水性薬物送達のための新規なポリマーベースのヒドロトロープ |
| DK3234134T3 (da) | 2014-12-17 | 2020-07-27 | Proqr Therapeutics Ii Bv | Målrettet rna-redigering |
| US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| US20180002702A1 (en) | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| US10792299B2 (en) | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| US11045488B2 (en) | 2014-12-26 | 2021-06-29 | Nitto Denko Corporation | RNA interference agents for GST-π gene modulation |
| PT3386519T (pt) * | 2015-12-13 | 2021-04-27 | Nitto Denko Corp | Estruturas de sirna para atividade elevada e redução de alvos extra |
| WO2017220751A1 (en) | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Single-stranded rna-editing oligonucleotides |
| ES2837076T3 (es) | 2016-09-01 | 2021-06-29 | Proqr Therapeutics Ii Bv | Oligonucleótidos para la edición de ARN de cadena sencilla modificados químicamente |
| JP6833456B2 (ja) | 2016-11-02 | 2021-02-24 | 日東電工株式会社 | 皮膚線維症処置剤 |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| US11274300B2 (en) | 2017-01-19 | 2022-03-15 | Proqr Therapeutics Ii B.V. | Oligonucleotide complexes for use in RNA editing |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| EP3946596A4 (en) * | 2019-03-27 | 2022-12-21 | Phoenix Tissue Repair, Inc. | SYSTEMS AND METHODS OF PRODUCING COLLAGEN COMPOSITIONS 7 |
| CN110237235B (zh) * | 2019-06-04 | 2023-03-28 | 徐州医科大学 | 华支睾吸虫重组蛋白CsHscB在胆汁淤积性肝纤维化治疗药物中的应用 |
| CN111135300A (zh) * | 2020-01-09 | 2020-05-12 | 南京大学 | 一种蛋白抑制剂在制备减轻雾霾引起肺炎的药物中的用途 |
| AU2021234324A1 (en) * | 2020-03-11 | 2022-09-29 | Proda Biotech L.L.C. | Methods for treating fibrosis using PKM2 activators |
| KR102404883B1 (ko) * | 2020-11-30 | 2022-06-07 | (주)이노보테라퓨틱스 | 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물 |
| CN116917480A (zh) * | 2021-01-15 | 2023-10-20 | 国立大学法人东京大学 | Rna分子、嵌合体型na分子、双链rna分子及双链嵌合体型na分子 |
| CN118891366A (zh) | 2022-03-16 | 2024-11-01 | 第一三共株式会社 | 抑制转铁蛋白受体2的表达的siRNA |
| CN118871585A (zh) | 2022-03-16 | 2024-10-29 | 第一三共株式会社 | 具有RNAi活性的化学-修饰的寡核苷酸 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4501729A (en) * | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| US4486194A (en) * | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) * | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| AU630076B2 (en) | 1987-09-21 | 1992-10-22 | Gen-Probe Incorporated | Non-nucleotide linking reagents for nucleotide probes |
| US5167616A (en) * | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US5214136A (en) * | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| DK1695979T3 (da) | 1991-12-24 | 2011-10-10 | Isis Pharmaceuticals Inc | Gappede modificerede oligonukleotider |
| AU687736B2 (en) | 1992-05-11 | 1998-03-05 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| WO1995006731A2 (en) | 1993-09-02 | 1995-03-09 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
| DE69433036T2 (de) * | 1993-09-03 | 2004-05-27 | Isis Pharmaceuticals, Inc., Carlsbad | Aminoderivatisierte nukleoside und oligonukleoside |
| US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| EP0725788B1 (en) | 1993-10-27 | 1998-12-16 | Ribozyme Pharmaceuticals, Inc. | 2'-amido and 2'-peptido modified oligonucleotides |
| US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| EP0755454B1 (en) * | 1994-04-13 | 2008-02-13 | The Rockefeller University | Aav-mediated delivery of dna to cells of the nervous system |
| US6447796B1 (en) * | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| CA2207593A1 (en) | 1994-12-13 | 1996-06-20 | John Gustofson | Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses |
| ATE373672T1 (de) * | 1996-01-16 | 2007-10-15 | Sirna Therapeutics Inc | Synthese von methoxynukleoside und enzymatische nukleisäure moleküle |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| US6235310B1 (en) | 1997-04-04 | 2001-05-22 | Valentis, Inc. | Methods of delivery using cationic lipids and helper lipids |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| KR100414936B1 (ko) | 1997-09-12 | 2004-01-13 | 엑시콘 에이/에스 | 이환 및 삼환 뉴클레오시드, 뉴클레오타이드 및올리고뉴클레오타이드 동족체 |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| EP1038016A2 (en) | 1997-12-16 | 2000-09-27 | Valentis Inc. | Needle-free injection of formulated nucleic acid molecules |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| EP2138191A1 (en) * | 1998-01-05 | 2009-12-30 | University Of Washington | Enhanced transport using membrane disruptive agents |
| AR020078A1 (es) | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| EP1096921B1 (en) | 1998-07-20 | 2003-04-16 | Protiva Biotherapeutics Inc. | Liposomal encapsulated nucleic acid-complexes |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| NZ513402A (en) * | 1999-02-12 | 2003-06-30 | Sankyo Co | Novel nucleosides and oligonucleotide analogues |
| EP1159441B8 (en) | 1999-03-10 | 2008-10-29 | Marie Curie Cancer Care | Delivery of nucleic acids and proteins to cells |
| JP2001031588A (ja) | 1999-07-21 | 2001-02-06 | Terumo Corp | 腹膜肥厚抑制剤 |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20070026394A1 (en) * | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| AU2001281730A1 (en) | 2000-07-26 | 2002-02-05 | Chemometec A/S | Spatially resolved enzyme-linked assay |
| RU2322500C2 (ru) * | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
| WO2002087541A1 (en) * | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
| US6586524B2 (en) | 2001-07-19 | 2003-07-01 | Expression Genetics, Inc. | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
| JP2003159087A (ja) | 2001-09-13 | 2003-06-03 | Japan Science & Technology Corp | 組織線維化抑制オリゴヌクレオチド |
| AUPR894201A0 (en) | 2001-11-19 | 2001-12-13 | Women's And Children's Hospital | Respiratory delivery for gene therapy and lentiviral delivery particle |
| US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| US7141540B2 (en) | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| US7795422B2 (en) * | 2002-02-20 | 2010-09-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA) |
| ES2280826T5 (es) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
| US20050106731A1 (en) | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
| WO2004014933A1 (en) | 2002-08-07 | 2004-02-19 | University Of Massachusetts | Compositions for rna interference and methods of use thereof |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| ES2576677T3 (es) | 2003-03-21 | 2016-07-08 | Roche Innovation Center Copenhagen A/S | Análogos de ARN interfirientes cortos |
| JP4605799B2 (ja) * | 2003-04-02 | 2011-01-05 | ダーマコン， インコーポレイテッド | Ｒｎａ干渉において使用するための修飾ポリヌクレオチド |
| US20040224405A1 (en) * | 2003-05-06 | 2004-11-11 | Dharmacon Inc. | siRNA induced systemic gene silencing in mammalian systems |
| ATE485394T1 (de) | 2003-06-02 | 2010-11-15 | Univ Massachusetts | Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai |
| US7750144B2 (en) * | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
| WO2005010213A2 (en) * | 2003-07-17 | 2005-02-03 | Pacific Edge Biotechnology, Ltd. | Markers for detection of gastric cancer |
| US20050136437A1 (en) * | 2003-08-25 | 2005-06-23 | Nastech Pharmaceutical Company Inc. | Nanoparticles for delivery of nucleic acids and stable double-stranded RNA |
| CN1845993B (zh) * | 2003-08-28 | 2010-06-23 | 诺瓦提斯公司 | 具有平端和3＇修饰的干扰rna双链体 |
| JP5243789B2 (ja) * | 2004-03-15 | 2013-07-24 | シティ・オブ・ホープ | 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための方法及び組成物 |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| KR101147147B1 (ko) * | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| US7842800B2 (en) * | 2004-04-02 | 2010-11-30 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof |
| CA2568735A1 (en) * | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| EP2990410A1 (en) * | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| US7358223B2 (en) | 2004-10-04 | 2008-04-15 | Nitto Denko Corporation | Biodegradable cationic polymers |
| AU2005300688B2 (en) * | 2004-11-03 | 2012-02-02 | Almac Diagnostics Limited | Transcriptome microarray technology and methods of using the same |
| WO2006047842A2 (en) | 2004-11-08 | 2006-05-11 | K.U. Leuven Research And Development | Modified nucleosides for rna interference |
| PT2730277T (pt) * | 2004-12-22 | 2020-04-21 | Nitto Denko Corp | Veículo de fármaco e kit de veículo de fármaco para a inibição da fibrose |
| JP2009221164A (ja) * | 2008-03-17 | 2009-10-01 | Nitto Denko Corp | 肺線維症処置剤 |
| US20060216722A1 (en) * | 2005-03-25 | 2006-09-28 | Christer Betsholtz | Glomerular expression profiling |
| JP5342834B2 (ja) * | 2008-09-05 | 2013-11-13 | 日東電工株式会社 | 骨髄線維症処置剤 |
| CN1840709B (zh) * | 2006-01-23 | 2010-05-26 | 南开大学 | 筛选与鉴定治疗免疫耐受相关疾病功能基因serpinh1的方法 |
| JP2008167739A (ja) * | 2006-06-14 | 2008-07-24 | National Institute Of Advanced Industrial & Technology | Ｒｎａ干渉効果が高い修飾型二本鎖ｒｎａ |
| EP2046993A4 (en) * | 2006-07-07 | 2010-11-17 | Univ Massachusetts | RNA SILENCING COMPOSITIONS, AND METHODS OF TREATING HUNTINGTON CHOREA |
| US20080132723A1 (en) * | 2006-12-04 | 2008-06-05 | Celanese International Corporation | Process for the production of ethylene, acetic acid and carbon monoxide from ethane |
| JP5252622B2 (ja) * | 2007-01-17 | 2013-07-31 | 独立行政法人産業技術総合研究所 | 高いヌクレアーゼ耐性と優れたｒｎａ干渉効果を発現可能な二本鎖ｒｎａ |
| US20100215588A1 (en) | 2007-04-26 | 2010-08-26 | Rami Skaliter | Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system |
| CA2698812A1 (en) * | 2007-09-14 | 2009-03-19 | Nitto Denko Corporation | Drug carriers |
| CA2701845A1 (en) * | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| CN102159247A (zh) * | 2008-07-30 | 2011-08-17 | 日东电工株式会社 | 药物载体 |
| AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
| TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
-
2010
- 2010-12-08 ES ES10836656.8T patent/ES2562499T3/es active Active
- 2010-12-08 WO PCT/US2010/059578 patent/WO2011072082A2/en not_active Ceased
- 2010-12-08 JP JP2012543268A patent/JP5685267B2/ja active Active
- 2010-12-08 TW TW103139983A patent/TWI543763B/zh active
- 2010-12-08 CN CN201610933224.7A patent/CN106701758B/zh active Active
- 2010-12-08 CN CN201080060946.7A patent/CN102741410B/zh active Active
- 2010-12-08 CA CA2781896A patent/CA2781896C/en active Active
- 2010-12-08 PT PT108366568T patent/PT2509991E/pt unknown
- 2010-12-08 KR KR1020157034827A patent/KR101692063B1/ko active Active
- 2010-12-08 AU AU2010328104A patent/AU2010328104B2/en active Active
- 2010-12-08 TW TW105114241A patent/TWI611021B/zh active
- 2010-12-08 PL PL10836656T patent/PL2509991T3/pl unknown
- 2010-12-08 CN CN201610933223.2A patent/CN106701757B/zh active Active
- 2010-12-08 KR KR1020127017729A patent/KR101718534B1/ko active Active
- 2010-12-08 KR KR1020167036618A patent/KR101900588B1/ko active Active
- 2010-12-08 TW TW099142975A patent/TWI465238B/zh active
- 2010-12-08 EP EP18191694.1A patent/EP3434773A3/en active Pending
- 2010-12-08 EP EP15193839.6A patent/EP3012324A3/en not_active Withdrawn
- 2010-12-08 DK DK10836656.8T patent/DK2509991T3/en active
- 2010-12-08 US US12/963,600 patent/US8710209B2/en active Active
- 2010-12-08 EP EP10836656.8A patent/EP2509991B1/en active Active
-
2012
- 2012-05-15 IL IL219804A patent/IL219804A/en active IP Right Grant
-
2014
- 2014-03-18 US US14/218,422 patent/US9206424B2/en active Active
-
2015
- 2015-01-16 JP JP2015006421A patent/JP5972408B2/ja active Active
- 2015-10-27 US US14/924,284 patent/US10093923B2/en active Active
-
2016
- 2016-02-05 JP JP2016020615A patent/JP6197057B2/ja active Active
- 2016-07-13 IL IL246770A patent/IL246770B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013514761A5 (enExample) | ||
| JP2016127853A5 (enExample) | ||
| JP2015109851A5 (enExample) | ||
| AU2022206704B2 (en) | Nanoparticle formulations for delivery of nucleic acid complexes | |
| EP2238251B1 (en) | Silencing of polo-like kinase expression using interfering rna | |
| US9074205B2 (en) | Nicked or gapped nucleic acid molecules and uses thereof | |
| ES2586593T3 (es) | Liposomas de retinoide para potenciar la modulación de la expresión de hsp47 | |
| CA2644347C (en) | Small internally segmented interfering rna | |
| US10041074B2 (en) | Euchromatic region targeting methods for modulating gene expression | |
| JP2023541404A (ja) | ＤＵＸ４の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用方法 | |
| US20150232847A1 (en) | Targeting oligonucleotides and related methods for modulating fxn rna | |
| US20150225722A1 (en) | Methods for selective targeting of heterochromatin forming non-coding rna | |
| JP2011519579A (ja) | 炎症および新生細胞増殖の治療のためのオリゴヌクレオチド | |
| EP3256590A1 (en) | Targeting oligonucleotides and uses thereof to modulate gene expression | |
| JP2020526192A (ja) | アルファ−ＥＮａＣの発現を阻害するためのＲＮＡｉ剤、および使用方法 | |
| JP2023501246A (ja) | ベータＥＮａＣの発現を阻害するＲＮＡｉ剤、その組成物および使用方法 | |
| CN117440817A (zh) | 用于抑制晚期糖基化终末产物受体表达的RNAi剂、其组合物和使用方法 | |
| JP7208911B2 (ja) | 核酸分子発現の調節 |